Vivesto AB VIVE
No full analysis yet
We have not published a full analysis of Vivesto yet. Follow the company free and we will monitor it and email you when we publish something — or run a quick check now.
Email when we publish an analysis or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Vivesto AB? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Vivesto free Follow freeEmail when we publish an analysis or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Vivesto AB (formerly Oasmia Pharmaceutical) is a Swedish oncology-focused biotech developing cancer treatments for both humans and animals. The company leverages its XR-17 formulation platform and advances projects such as Paccal Vet and Cantrixil, while Apealea is partnered out. The company is loss-making and depends on financing and study readouts for value creation.